BRIDGEWATER, N.J., Sept. 29, 2017 /PRNewswire/ -- Nevakar LLC, a privately-held specialty pharmaceutical company developing
"This research agreement with Princeton University furthers our efforts to develop enhanced and innovative products that leverage novel scientific and technology platforms," said Navneet Puri, Ph.D., founder and chief executive officer of Nevakar.
About Princeton UniversityPrinceton is a not-for-profit institution of higher education dedicated to advancing learning through scholarship, research, and teaching of unsurpassed quality, with an emphasis on undergraduate, and doctoral education that is distinctive among the world's great universities, and with a persuasive commitment to serve the nation and the world.
About NevakarNevakar is a specialty pharmaceutical company focused on therapies within the injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently FDA-approved molecules, through intensive R&D and clinical efforts. Nevakar has a comprehensive infrastructure for product development at its New Jersey facilities. More information about Nevakar can be found at www.nevakar.com.
CONTACTSAt Nevakar:Marshall Woodworth Chief Financial Officer(908) [email protected]
At Rx Communications Group:Paula Schwartz(917) [email protected]
View original content:http://www.prnewswire.com/news-releases/nevakar-announces-new-collaborative-research-agreement-with-princeton-university-300528170.html
SOURCE Nevakar LLC
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All